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Introduction: Loss of sensation due to diabetes-related neuropathy often leads to
diabetic foot ulceration. Several test instruments are used to assess sensation, such
as static and moving 2-point discrimination (S2PD, M2PD), monofilaments, and tun-
ing forks.
Methods: Mokken scale analysis was applied to the Rotterdam Diabetic Foot Study
data to select hierarchies of tests to construct measurement scales.
Results: We developed 39-item and 31-item scales to measure loss of sensation for
research purposes and a 13-item scale for clinical practice. All instruments were
strongly scalable and reliable. The 39 items can be classified into 5 hierarchically
ordered core clusters: S2PD, M2PD, vibration sense, monofilaments, and prior ulcer
or amputation.
Discussion: Guided by the presented scales, clinicians may better classify the grade
of sensory loss in diabetic patients’ feet. Thus, a more personalized approach con-
cerning individual recommendations, intervention strategies, and patient information
may be applied.
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1 | INTRODUCTION
Diabetic sensorimotor polyneuropathy (DSP) occurs in about 50% of
diabetic patients, leading to decreased quality of life and increased
mortality.1-3 Sensory loss due to DSP is one of the most important risk
factors for diabetic foot ulceration and amputation.4 DSP is frequently
accompanied by positive sensory phenomena. Yet, it is the simulta-
neous process of decreased sensation that places the feet of diabetic
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patients at risk.5 Because not every patient with positive sensory
symptoms has sensory loss, it is useful to focus on objective measures
such as foot sensation to assess large-fiber nerve function.6
Loss of sensation can be assessed with several instruments.7,8
Current guidelines recommend an annual screening with a 10-g
Semmes-Weinstein monofilament (SWM) or a tuning fork.9-11 These
instruments test different somatosensory corpuscles and nerve fibers,
functions of which are progressively lost during the natural course of
DSP.12-14 However, a cutaneous threshold of ≥10 g is an indicator of
large-fiber demyelination, which becomes informative in a late stage
of neuropathy and reflects a high risk for foot ulceration and lower
extremity amputation.15 Other measurements, such as 2-point dis-
crimination, have proven to be early indicators of nerve pathology and
may be able to detect earlier alterations in foot sensation.6,16,17
Few available studies have described the sequence in which sen-
sory tests become abnormal in the natural course of diabetes-related
neuropathy.6,18,19 To more precisely categorize patients with diabetes
according to their degree of sensory loss, we applied the Mokken
scale analysis (MSA), which is related to nonparametric forms of item-
response theory (IRT), to the tests used in the Rotterdam Diabetic
Foot (RDF) Study.6 MSA is a scaling method increasingly used in
health sciences.20-23 IRT assumes that a latent (not directly observ-
able) trait, denoted as θ (theta), drives the patients’ scores on the
items. Typically, θ is used as a proxy for the construct being measured
(ie, foot sensation, hence foot sensation determines the item scores).
Because θ is latent, a patient’s score on θ must be estimated from the
observable item scores.6,24 MSA is a flexible scaling method, in con-
trast to other IRT models such as Rasch analysis, so it fits data rela-
tively well and includes a fair amount of items that can be used for
ordinal measurement. In the present analysis, we used questionnaire
data and the results of sensory tests of the feet as items (RDF Study
Test Battery).
We investigated whether the tests of the RDF Study Test Battery
were unidimensional, scalable, and reliable in assessing sensation in
the feet. Information on the degree of sensory loss may help clinicians
to assess the risk of lower extremity complications, resulting in more
personalized recommendations regarding intervention strategies and
patient information.
2 | METHODS
2.1 | Study design and subjects
Between January 2014 and June 2015, patients were evaluated in the
outpatient Diabetes Clinic of the Franciscus Gasthuis in Rotterdam,
The Netherlands, as part of the RDF Study—a prospective cohort
study that investigates the deterioration of sensation in diabetic
patients’ feet over time. The RDF Study design and methods are
described in more detail in previous studies.6,25 Inclusion criteria
included patients diagnosed with diabetes mellitus (treated by oral
blood glucose–lowering drugs and/or insulin), who were ≥18 years
old, spoke Dutch or English, and had no significant cognitive impair-
ment. Exclusion criteria were assessed at the interview and with a
screening questionnaire and included a positive history of active radic-
ular syndrome or a neurological disease that interfered with sensation
in the feet. Demographic data were obtained from the patients’ files.
All subjects provided written informed consent. The institutional
review board and the medical ethics committee of Erasmus MC Uni-
versity Center, Rotterdam, The Netherlands, approved the study
(MEC-2009-148).
2.2 | Comparison with healthy controls without
known neuropathy
A total of 196 healthy volunteers were tested with the same measure-
ment instruments and the same protocol as the RDF Study population
as part of a separate study to obtain normative test values.26 Volun-
teers were recruited from hospital and university personnel and rela-
tives and friends of patients visiting the outpatient clinic. Patients
were included in the study if they were ≥18 years of age, had no sig-
nificant cognitive impairment, spoke Dutch or English, and provided
signed informed consent. Exclusion criteria were a positive history of
active radicular syndrome, a neurological disease that interfered with
sensation in the feet, diabetes mellitus, thyroid malfunction, alcohol
abuse, human immunodeficiency virus, or chemotherapy—all these
were established at the interview using a screening questionnaire.
Data sets were combined to compare patients with healthy controls.
2.3 | Measurement instrument
2.3.1 | Rotterdam Diabetic Foot Study Test Battery
Patients and volunteers were screened using monofilaments, static
and moving 2-point discrimination tests, a tuning fork, cold sensation
tests, the Michigan Neuropathy Screening Instrument (MNSI), and the
Romberg test. Information on prior ulceration and amputation, as indi-
cators of severe sensory loss, was retrieved from the patient’s file and
interview. Cutaneous threshold (1-point static discrimination, S1PD)
was tested on 5 locations of each foot using SWMs (Baseline; Tactile
Fabrication Enterprises, White Plains, NY, USA) ranging from 0.008 to
300 g. The test locations were chosen in concordance with the nerve
distribution in the foot (see Figure S1 online). Areas with excessive callus
formation were avoided. Innervation density (determined by static and
moving 2-point discrimination tests: S2PD and M2PD) was assessed on
the same test locations using a Disk-Criminator (US Neurologicals LLC,
Poulsbo, Washington, USA). M2PD was not assessed at the fifth toe
because the area is too small to conduct the test. A Rydel-Seiffer tuning
fork (Martin, Tuttlingen, Germany) tested the vibration threshold on the
medial malleolus and dorsal interphalangeal joint of the hallux. Both feet
were examined. Neuropathy symptoms were assessed using the MNSI
questionnaire, which was administered before the physical examination.
Using the Tinel sign, we scored localized nerve compression as
positive when tingling and electrical shocks were elicited after tapping
the tibial nerve at the left and right tarsal tunnel. To test cold percep-
tion, a cold piece of metal was bilaterally applied to the skin of the
foot arc. Proprioception was tested using the Romberg test.
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2.4 | Data analysis
A cross-sectional analysis of the RDF Study baseline data was carried
out for the MSA. Results from the RDF Study Test Battery (both tests
of sensation and questionnaire data) were dichotomized because
MSA requires that all items have the same number of categories. Indi-
vidual sensory test items were comprised of both a sensory test and
the test location (eg, S1PD at the hallux is labeled as S1PD I, and
S2PD at the medial heel as S2PD II). Based on previously published
normative values, the threshold for S2PD and M2PD was set at 8 mm
and at 10 g for S1PD.26 Vibration threshold was compared with age-
related reference values.27 Positive symptoms (eg, tingling and burn-
ing sensations) and negative symptoms (eg, numbness) were retrieved
from the MNSI questionnaire, resulting in two items. When scoring at
or below the threshold (ie, “could feel the stimulus”), 0 was noted. A
score of 1 was noted when a patient scored above the threshold,
meaning aberrant (ie, “could not feel the stimulus”). In total, 42 individ-
ual RDF Study Test Battery items were identified per subject. Second
and third annual follow-up data are presented and compared with
baseline data as a measure of the statistical significance of the change
scores.
2.5 | Mokken scale analysis
Refer to the supporting information available online for Mokken scale
analysis.28-38
2.6 | Person-item map
The ordering of the items along the latent trait (θ) was graphically dis-
played using a person-item map (PIM). The PIM shows the relation-
ship between the estimated item location parameters and the
estimated latent trait (ie, foot sensation), together with a histogram of
the estimated latent trait values.39 The map provides useful graphical
information on the ordering of items and the relationship between
items and persons.
2.7 | Statistics
MSA was conducted using the R package Mokken (R Foundation for
Statistical Computing).40,41 The PIM was constructed using the R
package eRm.50 Other statistical analyses were carried out using IBM
SPSS Statistics version 22.0 (IBM, Armonk, New York, USA). Missing
item data were replaced by imputed data using the procedure of
expectation maximization, using 25 iterations. The Shapiro–Wilk test
was used to assess normality. Because the majority of the variables
significantly deviated from a normal distribution, we continued our
analyses with nonparametric tests. Correlations between grading scale
scores and demographic characteristics of the control population were
investigated using Spearman coefficients. Using the Mann–Whitney
U test, we compared differences between total item scores of RDF
Study participants and controls without neuropathy as well as differ-
ences in grading scale scores between genders. Differences in grading
scale scores of subjects with a second and third follow-up were
assessed using the Friedman test. Spearman coefficients were used to
determine the direction and magnitude of the correlations or differ-
ences between these change scores (as a measure of responsiveness),
with the null hypothesis that no differences exist in foot sensation
during follow-up. P < .05 (two-sided) was considered statistically
significant.
3 | RESULTS
3.1 | General characteristics
A total of 416 diabetic patients with varying degrees of symptoms
and loss of sensation were included in the RDF Study. Table S1
(online) shows the general characteristics of the patients. Fifty-two
patients had a prior ulcer, and thirteen patients had a history of lower
extremity amputation.
3.2 | Mokken scale analysis
Under the monotone homogeneity model, the automated item-
selection procedure selected 39 of the original 42 items (Table S2
online). The items “Tinel sign left” and “Right” and “MNSI-positive
symptoms” were not selected, so the 40-point scale ranges from
0 (no aberrant tests) to 39 (all tests aberrant). Scalability coefficient
(Hi) values ranged from 0.354 to 0.713 (Table S2 online, third column),
with a coefficient of scalability of H = 0.538, which indicates a strong
scale—except for the item “Amputation left,” for which Hi > 0.8. The
Molenaar-Sijtsma statistic, ρ = 0.964, suggested that the 39-item scale
(RDF-39) is highly reliable. Of the 39 items, no items showed a viola-
tion of monotonicity. The most frequent aberrant items (eg, on S2PD
and M2PD) represent early stages of sensory loss (Table S2 online,
second column). Sensory functions were lost symmetrically, with
items representing more distal test sites (eg, vibration sense at the
interphalangeal joint) becoming aberrant before the proximal ones (eg,
vibration sense at the medial malleolus).
Under the double monotonicity model, the manifest invariant
item-ordering procedure selected 8 items violating IIO. The remaining
scale consisted of 31 items (RDF-31) and had an HT coefficient of
0.581. Hi values ranged from 0.431 to 0.836 and featured an
H = 0.550, which indicates a strong scale. The reliability statistic (ρ)
was 0.958.
3.3 | Person-item map
A PIM showed that the 39 items of the RDF-39 could be classified
into five core clusters (Figure S2 online). The S2PD cluster contained
the items that were first becoming aberrant during the natural history
of sensory loss, followed by a cluster of all M2PD items, vibration
sense items, S1PD items, and items on prior ulceration/lower extrem-
ity amputation.
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3.4 | Clinically applicable screening scale
Table S2 (online, sixth column) shows the item selection that we used to
construct a clinically applicable screening scale, based on the 31-item
scale. This 13-item scale (RDF-13) examines both extremities; items fea-
ture scalability coefficients ranging from 0.404 to 0.736 with H = 0.551,
which indicates a strong scale. The reliability coefficient suggests that
the scale is also reliable. Strong positive correlations have been found
between the 39-item scale and the 31-item scale, rs = 0.993, P < .001,
and 31-item scale and 13-item scale, rs = 0.966, P < .001. The item-
response functions for the 13-item scale were plotted (Figure 1), show-
ing their different discriminatory values along the sum score. As the
latent trait increases (indicative of more severe sensory loss), so does the
chance of obtaining an aberrant item test result. A clinically applicable
scoring sheet for the respective scales is shown in Table S3 (online).
3.5 | Comparison to healthy controls
A total of 196 healthy volunteers, with a median age of 50.5 (inter-
quartile range [IQR], 36.5-65.7) years, served as the control group—66
men (median age, 50.6 years; IQR, 37.7-64.1 years) and 130 women
(median age, 50.0 years; IQR, 33.3-66.9 years).26 The median height for
this group was 172.0 (IQR, 166.3-178.8) cm and the median weight
72.0 (IQR, 63.0–82.0) kg. Diabetic subjects were significantly older and
heavier than controls (P < .0005; Table S1 online).
Figure 2 shows the 39-item sum-score distribution of diabetic
RDF Study participants compared with the controls. Median total
RDF-39 scores differed significantly between individuals in the
control group (5.5; IQR, 3.0-10.8) and RDF Study subjects with
diabetes (17; IQR, 9.0-22.0) (P < .0001).
Because diabetes-related lower extremity complications (ie, neu-
ropathy symptoms, sensory loss, ulceration, and amputations) are the
main drivers of RDF-39 scores in diabetic subjects, correlations
between RDF-39 scores and demographic variables, such as age,
height, and weight, were only explored in the control population. Sig-
nificant positive correlations were found between RDF-39 scores and
F IGURE 1 Item-characteristic curve
of the 13-item scale. The ICC curves of
items “Vibration sense IP left” and “Right”
are plotted on top of each other. I, plantar
hallux; II, medial heel; IP, interphalangeal
joint; MM, medial malleolus [Color figure
can be viewed at wileyonlinelibrary.com]
F IGURE 2 Sum-score distribution of the 39-item scale in diabetic
patients and controls without known neuropathy [Color figure can be
viewed at wileyonlinelibrary.com]
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age (rs = 0.405, P < .0005) and RDF-39 scores and weight (rs = 0.212,
P = .003). A nonsignificant positive trend was observed between
RDF-39 scores and height, rs = 0.135, p = 0.059. Nonsignificant differ-
ences in median RDF-39 scores (IQR) were found between males (6.0;
IQR, 3.0-12.5) and females (5.0; IQR, 2.8-10.0) (P = .563).
3.6 | Responsiveness of RDF-39
We conducted a Friedman test to determine whether there were differ-
ences inwithin-subjects’ RDF-39 scores, which were collected during fol-
low-up of the RDF study (n = 135). RDF-39 scores at baseline (median,
17; IQR, 17-22), at the 1-year follow-up (median, 16; IQR, 16-24), and
at 2-year follow-up (median, 18; IQR, 18-22) did not differ significantly
(χ2 (2) = 1.536, P = .464). Therewas a strong positive correlation between
baseline and first follow-up RDF-39 scores (rs = 0.698, P < .0005) and
between first and second follow-up scores (rs = 0.697, P < .0005).
4 | DISCUSSION
This quantitative assessment of the categorical loss of pedal sensation
of patients with diabetes has shown that the ability to sense S2PD,
M2PD, vibration, and S1PD disappears in this order. This study has
emphasized the added value of testing static and moving 2-point dis-
crimination and highlights the importance of test locations in the
screening of diabetic patients. Furthermore, the instruments (RDF-39,
−31, and − 13) captured the functional loss that is dictated by the
pathophysiology of neuropathy.16,18,19
At present, no data are available on how a tuning fork, monofilament
testing, and test locations compare or how these should be interpreted.11
By taking the site of screening into account, we observed that the first
dorsal web and the lateral foot are the last of all sensibility tests and loca-
tions to become the least sensitive to the 10-g monofilament. This may
have predictive value for future lower extremity complications because it
suggests substantial deafferentation. Originally, the monofilament was
studied as a prognostic indicator of ulceration and amputation.42,43 Now-
adays, the validity of the monofilament examination to identify the pres-
ence of DSP is generally accepted.44,45 Because the onset of sensory loss
is insidious, its diagnosis may be difficult. Several scoring systems for
signs and symptoms of DSP have been developed, but they can be com-
plex and time-consuming.46 Electrodiagnostic techniques do not assess
all nerve fibers undergoing changes in diabetes and may be technically
challenging on the plantar surface of the foot.47,48 It has been rec-
ommended that the diagnosis of DSP requires a test battery, with high
sensitivity, that can detect early or mild forms in low-risk populations.49
Furthermore, it is important for population studies to possess screening
tools that are reproducible, sensitive, and fast to carry out. The simple-to-
use instruments used in the presented scales fulfill these criteria and are
already being applied in clinical practice. These scales can quickly and reli-
ably estimate skin sensation and may be easily implemented by nurses,
nurse practitioners, and physicians treating diabetic patients.
MSA is also a flexible scaling method. More restrictive scaling
methods, such as Rasch analysis, typically fit the data worse (ie, the
data are not well-described by the Rasch model) and include relatively
few items in the scale. However, the scales allow interval measure-
ment.6 We believe ordinal measurement is sufficient for our study
because the 40 ordinal levels of pedal sensory function produced by
the 39-item scale are very informative. Most of the included items are
indicators of large-fiber function; however, some items assessed small-
fiber function (items “cold perception left” and “right”). We included
these items to investigate how they become aberrant in the natural
course of sensory loss, as compared with large-fiber function. Our data
show that the ability to detect a cold stimulus decreases at a late stage
of sensory loss, just before abnormal monofilament tests on the first
dorsal web and lateral foot. However, the exact temporal sequence in
which the different nerve fibers lose their functions is not fully under-
stood.19,50 MSA may aid in this debate in future studies.
The results of our study confirm that a patient most often first
loses sensation in the distal extremity, with vibration sense lost at the
interphalangeal joint of the hallux before the medial malleolus. The
scales also show that a patient loses sensation in both legs symmetri-
cally, which is in line with the definition of DSP being a distal, sym-
metrical neuropathy.49 The item on numbness of the feet is
positioned after the items on S2PD, M2PD, and vibration sense,
which is of interest and suggests that patients seem unaware of the
loss of these sensory modalities. At the same time, axonal density
decreases, indicating that the feet are likely already at risk.51 The
39-item and 31-item scales (RDF-39 and -31) were developed for
research purposes, yet they can also be used for patient-level mea-
surements. The short 13-item (RDF-13) scale may help with individu-
alized medical decision-making and may serve as a complement to the
current prediction models for lower extremity complications.52-55
An automated item-selecting procedure ruled out the items “Tinel left”
and “Right” and “MNSI-positive symptoms,”meaning that they did not pass
the marginal test for fitting the monotone homogeneity model. These
items do not hold a robust position in the natural course of the disease, as
clinicians will recognize from daily practice—patients who have had an ulcer
and patients without aberrant large-fiber function (eg, intact S2PD) may
still complain of painful neuropathic symptoms. As these results suggest,
subjective positive symptoms do not necessarily correlate with the degree
of sensory loss, which is in contrast to negative symptoms experienced,
such as “numbness,”which does have a robust position on the scale.
In our study, 44.9% (95% CI, 40.1%-49.7%) of diabetic patients
exhibited signs of tibial nerve compression, as indicated by a positive
Tinel sign at the tarsal tunnel.25 However, we also found that this sign
had an uncertain place in the natural course of sensory loss; the Tinel
sign items were not selected by the models and therefore were not
included in the scales. This exclusion may be explained by the patho-
physiology behind this diagnostic tool—demyelination and axonal
sprouting elicit a positive sign, but a negative sign is reported when
those phenomena have not yet occurred or when the nerve has been
irreversibly damaged.56 Therefore, sensitivity/specificity calculations
are not appropriate because they only can be interpreted when the
degree of nerve damage is known.57,58
The population of the RDF Study has a wide variation sensory
loss, with and without symptoms of DSP, resulting in a low risk of
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spectrum bias. Therefore, we believe that the external validity of our
findings is likely to be high. By comparing the distribution of the sum
score of diabetic subjects to that of healthy volunteers without known
neuropathy, we confirmed our hypothesis that the instruments cor-
rectly categorize patients’ sensation in the feet. However, due to prior
dichotomization of items, with the threshold set at 8 mm for items on
static and moving 2-point discrimination, we noted some aberrancy in
the first 18 items (S2PD and M2PD) assessed in the healthy controls.
Decline in foot sensation due to age was confirmed in our analysis,
with age being the most important determinant.59 Only nonsignificant
differences were observed between genders, which is in line with pre-
vious reports.7,26,60 The observed association between weight and
foot sensation is presumably confounded by (components of) the
metabolic syndrome, as it relates to polyneuropathy, and should be
investigated in future studies.61 The most important risk factors for
DSP relate to the duration of diabetes, control of glucose levels, and
the existence of cardiovascular risk factors.62,63 We retained the null
hypothesis that no differences existed in foot sensation in this time-
frame. A follow-up of this cohort will reveal which time-frame is appli-
cable on the progressive steps on the scale, as well as the associated
risk for (re-)ulceration or amputation, per sum score.15
In conclusion, MSA has revealed new dimensions in the use of
current screening instruments in this diverse diabetic population.
Based on the presented scales, clinicians may better categorize
patients’ loss of sensation in their feet. Therefore, an individualized
approach with recommendations regarding intervention strategies
and patient information may be feasible.64-67
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